Bernina BioInvest
VC Fund
Zug, Switzerland
Bernina BioInvest is an investment Firm.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Bernina BioInvest invests in
BiotechnologyHealth CareMedicalPharmaceuticalBiopharma
Stages Bernina BioInvest invests in
SeedSeries ASeries BFunding RoundVenture - Series Unknown
Countries Bernina BioInvest invests in
Switzerland
Round sizes
Seed $1.5M–$20MSeries A $15M–$65M
Round size
- Seed
- $1.5M–$20M
- Series A
- $15M–$65M
Investment Focus
Industry
- Biotechnology 6 (38%)
- Health Care 5 (31%)
- Medical 3 (19%)
- Pharmaceutical 3 (19%)
- Biopharma 2 (13%)
Stage
- Seed 5 (31%)
- Series A 3 (19%)
- Series B 1 (6%)
- Funding Round 1 (6%)
- Venture - Series Unknown 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $65M / Series A / May 08, 2025 | ||
| Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNAmolecules for customized protein expression and modification in multiple disease areas with high unmet medical need. | $10M / Seed / Jun 14, 2023 | ||
| HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $5M / Seed / Feb 09, 2022 | ||
| HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $20.1M / Seed / May 20, 2021 | ||
| HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $18M / Seed / May 05, 2021 | ||
| Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the naturalfunctioning of the brain.The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need. | $21.9M / Series A / Nov 12, 2020 | ||
| Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $15.6M / Series B / Nov 06, 2020 | ||
| Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNAmolecules for customized protein expression and modification in multiple disease areas with high unmet medical need. | $6.4M / Seed / Jul 15, 2020 | ||
| ELDICO Scientific AG (The Electron Diffraction Company) is a Swiss hardware company founded in 2019 and based in the Switzerland Innovation Park Innovaare at the Paul Scherrer Institute (PSI), a globally leading Swiss research institute for natural and engineering sciences. ELDICO develops, manufactures and sells novel instruments for electrondiffraction in crystallography, enabling nanocrystalline solid state analysis in the sub-micrometer range. Specific instruments are not yet available on the market today. ELDICO will be launching the first instrument specifically designed for nano-crystallographic investigations. The proof of concept was achieved in 2018 (ETH Zurich, C-CINA Basel) as part of a Nano-Argovia project of the Swiss Nanoscience Institute (SNI) on scientifically and industrially relevant samples. It was published in 2018 and awarded as a Top 5 "Breakthrough of the Year 2018" by leading scientific journal SCIENCE. In 2020, ELDICO took second place in the competition for the prestigious pioneer prize awarded by Technopark Zurich and the Zürcher Kantonalbank (ZKB). | $1.5M / Seed / May 07, 2020 | ||
| ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease. | $15.2M / Series A / Dec 10, 2019 | ||
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
Health Care Investors
48,627 investors
Biotech Investors
24,131 investors
Biotechnology Investors
21,397 investors
Medical Investors
21,234 investors
Health Care VC Funds
36,465 investors
Biotech VC Funds
20,850 investors
Biotechnology VC Funds
18,763 investors
Medical VC Funds
18,263 investors
Health Care Angel Investors
12,162 investors
FAQ
What does Bernina BioInvest invest in?
Bernina BioInvest invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 16 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Bernina BioInvest's check size?
Bernina BioInvest typically joins rounds of $1.5M–$20M at Seed and $15M–$65M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Bernina BioInvest participates in.
When did Bernina BioInvest last invest?
The most recent investment recorded for Bernina BioInvest closed in May 2025. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
